Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
暂无分享,去创建一个
Ying Huang | D. Benson | Y. Efebera | A. Rosko | S. Devarakonda | M. Chaudhry | A. Khan | F. Cottini | N. Williams | N. Bumma
[1] J. Byrd,et al. T-cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Mims,et al. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. , 2019, Clinical lymphoma, myeloma & leukemia.
[3] T. Koru-Sengul,et al. Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience , 2019, Blood.
[4] M. Dhodapkar,et al. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma , 2019, Clinical Cancer Research.
[5] M. Fine,et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America , 2019, American journal of respiratory and critical care medicine.
[6] N. Mahmud,et al. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant , 2019, Bone Marrow Transplantation.
[7] P. Sonneveld,et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.
[8] H. Goldschmidt,et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. , 2019, The New England journal of medicine.
[9] S. Lonial,et al. High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[10] H. Einsele,et al. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy , 2018, Journal of Cancer Research and Clinical Oncology.
[11] F. van Rhee,et al. Infectious and immunological sequelae of daratumumab in multiple myeloma , 2018, British journal of haematology.
[12] G. Ippolito,et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[13] M. Caligiuri,et al. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells , 2018, Clinical Cancer Research.
[14] Andre H Crepaldi,et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma , 2017, The New England journal of medicine.
[15] B. Barlogie,et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial , 2017, The Lancet.
[16] H. Goldschmidt,et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[17] A. Palumbo,et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[18] R. Greil,et al. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM) , 2016, American journal of hematology.
[19] Bie M. P. Verbist,et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.
[20] Chao Lu,et al. Retrospective study , 2016, Medicine.
[21] Camille Guillerey,et al. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies , 2016, Cellular and Molecular Life Sciences.
[22] S. Trudel,et al. Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant , 2015, Leukemia & lymphoma.
[23] U. Mellqvist,et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.
[24] Su-Jin Shin,et al. Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma , 2013, Korean journal of pathology.
[25] Je-Jung Lee,et al. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens , 2013, International Journal of Hematology.
[26] J. Trapani,et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. , 2011, Blood.
[27] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[28] A. Dispenzieri,et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study , 2008, British journal of haematology.
[29] R. Mesa,et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia , 2005, Leukemia.
[30] M. Naunton. Lenalidomide and dexamethasone for multiple myeloma , 2013 .
[31] D. Crivellari,et al. A Single-Institution Experience , 2013 .
[32] A. Palumbo,et al. Multiple myeloma. , 2011, The New England journal of medicine.
[33] A. Schwarer,et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.